Pine Valley Investments Ltd Liability Co Purchases 146 Shares of Stryker Co. (NYSE:SYK)

Pine Valley Investments Ltd Liability Co increased its position in shares of Stryker Co. (NYSE:SYK) by 6.7% in the 4th quarter, HoldingsChannel reports. The fund owned 2,324 shares of the medical technology company’s stock after acquiring an additional 146 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in Stryker were worth $839,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the 4th quarter worth approximately $33,000. Darwin Wealth Management LLC acquired a new position in Stryker during the 3rd quarter valued at approximately $36,000. Finally, Activest Wealth Management acquired a new position in Stryker during the 4th quarter valued at approximately $36,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $390.57 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The business has a 50-day moving average price of $378.78 and a 200 day moving average price of $370.22. The firm has a market cap of $149.03 billion, a PE ratio of 50.33, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm posted $3.46 earnings per share. Sell-side analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Analyst Ratings Changes

A number of brokerages have issued reports on SYK. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Wells Fargo & Company upped their price target on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada upped their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.